H.C. Wainwright raised the firm’s price target on Tarsus Pharmaceuticals (TARS) to $88 from $72 and keeps a Neutral rating on the shares. The firm upped its sales estimates for Xdemvy ahead of the Q3 results based on its conviction in the launch trajectory.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TARS: